Kainate receptor Inhibitors
1 drugsAbout Kainate receptor
Kainate receptors are ionotropic glutamate receptors involved in excitatory neurotransmission in the central nervous system. Activated by glutamate and kainic acid, they participate in various physiological processes by modulating neuronal excitability.
Kainate receptors are potential drug targets due to their role in neuronal signaling pathways implicated in various diseases. Currently, there is no genetic evidence directly linking Kainate receptors to specific diseases, but their role in modulating neuronal excitability makes them attractive targets.
There is one FDA-approved drug, QSYMIA, targeting Kainate receptors for metabolic indications. QSYMIA, developed by VIVUS LLC, was first approved in 2012 and remains the only approved drug in this space.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Healthy Volunteers with only 1 trials.
Top Kainate receptor Drugs
VIVUS LLC is the only company with an approved drug targeting Kainate receptors.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's tractability.
Kainate receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Kainate receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Kainate receptor Clinical Trials 20 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 1 | 0 | 67% |
| Phase 2 | 8 | 4 | 2 | 2 | 67% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 7 | 5 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Kainate receptor Drug Approval Timeline (2012 - 2012)
The first and only drug, QSYMIA, was approved in 2012.
The lack of recent approvals suggests a saturated market or challenges in developing new Kainate receptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting Kainate receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities